Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) is one of 279 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Monte Rosa Therapeutics to similar companies based on the strength of its risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.
Institutional and Insider Ownership
83.2% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 46.5% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 3.5% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 15.9% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Monte Rosa Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics’ peers have a beta of 1.07, indicating that their average stock price is 7% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Monte Rosa Therapeutics | 0 | 1 | 3 | 0 | 2.75 |
| Monte Rosa Therapeutics Competitors | 1035 | 4097 | 11172 | 172 | 2.64 |
Monte Rosa Therapeutics currently has a consensus target price of $18.40, suggesting a potential upside of 274.75%. As a group, “Biological products, except diagnostic” companies have a potential upside of 72.16%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than its peers.
Profitability
This table compares Monte Rosa Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Monte Rosa Therapeutics | N/A | -36.46% | -30.76% |
| Monte Rosa Therapeutics Competitors | -4,287.04% | -143.95% | -40.89% |
Valuation & Earnings
This table compares Monte Rosa Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Monte Rosa Therapeutics | N/A | -$108.50 million | -2.14 |
| Monte Rosa Therapeutics Competitors | $700.18 million | $87.49 million | -2.95 |
Monte Rosa Therapeutics’ peers have higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
Monte Rosa Therapeutics beats its peers on 9 of the 13 factors compared.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-tbk-logo.png&h=45&w=95&zc=2){kind=logo}
-tbk-logo.png&h=45&w=95&zc=2){kind=logo}